Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
Status:
Terminated
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
TrRaMM-TMI is a phase I trial to evaluate the feasibility and efficacy of an original
sequential TMI/TrRaMM (Total Marrow Irradiation/Treosulfan-Rapamycin-Mycophenolate Mofetil)
schedule in patients with hematological malignancies in advanced stage of disease undergoing
an allogenic Stem Cell Transplant (SCT).
The aim is to determine the maximum tolerated dose of TMI when combined with conditioning
chemotherapy to transplant according to TrRaMM schedule.